<DOC>
	<DOC>NCT02721966</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period, according to assessment of spondyloarthritis international society (ASAS) recommendations for the treatment of axial spondyloarthritis (AxSpA).</brief_summary>
	<brief_title>Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Written informed consent must be obtained before any assessment is performed Diagnosis of psoriatic arthritis classified by Classification criteria for psoriatic arthritis (CASPAR) criteria Active spinal disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) score ≥ 4 Spinal Pain visual analog scale (VAS) ≥ 40 (on a VAS 100 scale) Inadequate Response to at least 2 nonsteroidal antiinflammatory drugs over a 4 weeks period History of exposure to other IL17 or IL23 inhibitor biologic drug History of exposure to previous biologic disease modifying antirheumatic drugs (DMARDs) (Tumor necrosis factor (TNF) blockers or Ustekinumab) Current treatment with disease modifying antirheumatic drugs (DMARDs) other than Methotrexate Subjects taking high potency opioid analgesics (e.g. methadone, hydromorphone, morphine) Chest Xray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Assessment of spondyloarthritis international society (ASAS)</keyword>
	<keyword>ASAS</keyword>
	<keyword>axial</keyword>
	<keyword>Psoriatic Arthritis (PsA)</keyword>
	<keyword>PsA</keyword>
	<keyword>Magnetic resonance imaging (MRI)</keyword>
	<keyword>MRI</keyword>
</DOC>